Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?
Elie El Rassy1, Ziad Bakouny1, Tarek Assi1
1Department of Medical Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
Aim:
To determine which of the CDK4/6 inhibitors is the optimal treatment in metastatic luminal breast cancer.
Materials & Methods:
A network meta-analysis using the frequentist approach and generalized pairwise modeling was computed.
Results:
The associations of aromatase inhibitor with ribociclib, palbociclib and abemaciclib were similar in efficacy. Palbociclib-based regimen was associated with significantly lower treatment discontinuation rates compared with the other approved drugs in this indication.
Conclusion:
In the absence of direct comparative evidence, the results of this network meta-analysis represent the best available evidence for decision making in the first-line treatment of metastatic luminal breast cancer.
Insights
This study compared CDK4/6 inhibitors for metastatic luminal breast cancer. Palbociclib showed similar efficacy to other CDK4/6 inhibitors but had lower discontinuation rates.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic luminal breast cancer requires effective first-line treatments.
- Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are a key therapeutic class.
Purpose of the Study:
- To identify the optimal CDK4/6 inhibitor for first-line treatment in metastatic luminal breast cancer.
- To compare the efficacy and safety of CDK4/6 inhibitors in this patient population.
Main Methods:
- A network meta-analysis was conducted using a frequentist approach.
- Generalized pairwise modeling was employed to compare treatments.
Main Results:
- Ribociclib, palbociclib, and abemaciclib demonstrated similar efficacy when combined with aromatase inhibitors.
- Palbociclib-based regimens were associated with significantly lower treatment discontinuation rates compared to other CDK4/6 inhibitors.
Conclusions:
- This network meta-analysis provides the best available evidence for first-line treatment decisions in metastatic luminal breast cancer.
- While efficacy was comparable, palbociclib's lower discontinuation rate may favor its use.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:16Electric Potential and Potential Difference
When a test charge moves from the initial to the final position, the electric potential difference between those positions is defined as the ratio of the change in the potential energy to the charge on the...
01:05Difference from Background: Limit of Detection
The LOD indicates the presence or absence...
01:14Identifying Statistically Significant Differences: The F-Test
01:22Sum and Difference OpAmps
A summing amplifier, or an adder, utilizes an op-amp to merge multiple input signals into a single output signal. When audio signals are introduced into its input channels, the input resistors initiate currents that traverse feedback resistors, resulting in an output voltage. Applying Kirchhoff's current...